The Multidisciplinary Thoracic Cancers Symposium brings oncology professionals together to discuss ways to best treat people with lung cancer and other thoracic cancers. Dr. Nathan Pennell describes some of the research presented on targeted therapy, radiation therapy, and health disparities.
Recent FDA approvals for immunotherapy drugs for treating lung cancer are exciting, but there still are many things we need to learn about this new field of cancer treatment. Cancer.Net Associate Editor Jyoti Patel, MD, answers some of the questions that surround lung cancer and immunotherapy, during Lung Cancer Awareness Month.
Wrapping up our summer Research Round Up series, experts discuss advances in lung cancer and melanoma research.
Oncology professionals from around the world are in Chicago for the ASCO Annual Meeting. There, they will discuss the latest advances and newest thoughts in cancer research. Some of those advances focus on improving the quality of care and patients’ access to it.
These studies from the ASCO Annual Meeting show some of the newest thoughts and latest advances in using immunotherapy and targeted therapy to treat bladder, stomach, and lung cancers.
Patient advocate Dusty Donaldson reports from the 2016 Cancer Survivorship Symposium and discusses the growing support for survivorship care plans for all people with cancer.
What is low dose CT screening for lung cancer? What are the benefits and risks? Should I ask my doctor about it? In this podcast, Dr. Bernardo Goulart answers these questions and more.
Immunotherapy is one of the hottest topics in cancer research. This year, focus at the ASCO Annual Meeting has been on a type of immunotherapy called PD-1 inhibitors. Learn how these drugs may help improve the treatment of head and neck, liver, and lung cancers.
In this podcast, experts discuss ASCO’s recent endorsement of ASTRO’s guideline for radiation therapy for non-small cell lung cancer.
Dr. Julie Brahmer from the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins shares details about the recent FDA approval of nivolumab (Opdivo) for advanced non-small cell lung cancer. She explains how this impacts the treatment of lung cancer.